---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-019130"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T08:35:24.271886+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences Q1 net loss narrows to $25.1M; cash runway through Q1 2025

## Summary
- Net loss of $25.1M ($0.23/sh) vs $28.2M ($0.46/sh) in Q1 2022; revenue rose to $8.8M from $3.3M on Novartis agreement.
- Cash and equivalents $158M; expects runway through Q1 2025.
- Azer-cel: 7 patients in expansion cohort; PBCAR19B: 7 at Dose Level 2; updates expected May 2023.
- In vivo: PBGENE-HBV targeting CTA/IND in 2024; DMD data at ASGCT; R&D Day mid-2023.
- IP: Patent allowed for PCSK9-specific ARCUS nuclease for cardiovascular and gene insertion.

## SEC filing metadata
- accession: 0000950170-23-019130
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000095017023019130/0000950170-23-019130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000095017023019130/dtil-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-019130
- JSON: https://secwatch.observer/filing/0000950170-23-019130.json
- Plain text: https://secwatch.observer/filing/0000950170-23-019130.txt

## Key facts
- Earnings Releases
  PRECISION BIOSCIENCES INC reported financial results for the first quarter ended March 31, 2023.
  - Period: the first quarter ended March 31, 2023
  - Result: reported results
  source text: On May 9, 2023, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1357874/000095017023019130/0000950170-23-019130-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.